Skip to main content
Fig.Ā 3 | Clinical Sarcoma Research

Fig.Ā 3

From: A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosis

Fig.Ā 3

Clinical outcomes for TCGA soft tissue sarcoma patients (nā€‰=ā€‰206). a Kaplanā€“Meier curve of overall survival for CDKN2A altered versus non-CDKN2A altered patients (Cox Proportional Hazards adjusted for age, stage, and tumor size, pā€‰=ā€‰0.002). b Kaplanā€“Meier curve of survival by sarcoma histologies shows no significant difference in survival overall (pā€‰=ā€‰0.392). c Histologic distribution of patients who are CDKN2A wild type c versus CDKN2A altered d shows increase in proportion of MPNST, MFS, and UPS with decrease in LMS and DDLPS

Back to article page